A multidisciplinary team of researchers has developed an artificial intelligence platform that could enable doctors to prescribe personalized...
News
Early Signs of Efficacy Seen With Mesothelin CAR T-Cell Therapy
Mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy has shown early evidence of efficacy in a phase I trial of patients with...
Minimal residual disease analysis in myeloma – when, why and where
The primary hurdle in the path to curing multiple myeloma (MM) is defining a validated minimal residual disease (MRD) and its utility in the...
Many questions to ask in setting national coverage for CAR-T Therapies
Next week, a CMS committee will hold a daylong meeting to discuss a national coverage determination (NCD) for chimeric antigen receptor (CAR) T-cell...
Scientists race to improve ‘living drugs’ to fight cancer
Aaron Reid is lying in a hospital bed at the National Institutes of Health Clinical Center when doctors arrive to make sure he's ready for his...
Dr. Munshi on latest treatment developments in multiple myeloma
US FDA approves first non-gene edited allogeneic CAR T-cell candidate for trials
Unlike gene-edited CAR T-cell therapies, this approach does not cut the genome to knock out, or knock in, a gene, says Celyad. Read more:...
Lenalidomide-based maintenance therapy may be the most effective in myeloma
Continuous therapy with lenalidomide may lead to the greatest improvements in survival outcomes among patients with newly diagnosed multiple myeloma...
University hospitals seidman cancer center launches new CAR-T therapy trial
University Hospitals Seidman Cancer Center launched a new clinical trial for CAR-T, joining a select group of hospitals offering the therapy and a...
Pediatric CAR T-cell therapy guidelines highlight need for interdisciplinary monitoring
Children treated with chimeric antigen receptor T-cell therapy experience unique toxicities that require careful monitoring to prevent serious...
Selecting a proteasome inhibitor in multiple myeloma
Panelists: A. Keith Stewart, MB, ChB, Mayo Clinic; Sagar Lonial, MD, FACP, Emory University School of Medicine; Thomas Martin, MD, UCSF Helen Diller...
Pre-cancer bone health may help to predict myeloma outcomes
When it comes to multiple myeloma, patients’ bone health can have major implications on their outcomes – even before they are diagnosed, according...